The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice

Vaccine. 2011 Jun 6;29(25):4256-63. doi: 10.1016/j.vaccine.2011.03.040. Epub 2011 Mar 27.

Abstract

Here we evaluated the suitability of the synthetic adjuvant IC31® to potentiate the protective capacity of PD5 protein (domain III of the envelope protein of dengue 2 virus fused to the carrier protein P64k). Unlike Alum, PD5 mixed with IC31® induced complete protection against virus challenge in mice and increased IFN-γ secretion after in vitro re-stimulation. The induced antibody response was highly specific to the homologous serotype and showed both IgG1 and IgG2a subtypes. IC31® is a promising adjuvant for PD5 recombinant protein based vaccination against dengue. Future work should address the suitability of PD5/IC31® formulations in non-human primate models.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Animals
  • Antibodies, Viral / blood
  • Antigens, Viral / immunology*
  • Dengue / prevention & control*
  • Dengue Vaccines / administration & dosage
  • Dengue Vaccines / immunology*
  • Dengue Virus / immunology*
  • Drug Combinations
  • Female
  • Immunoglobulin G / blood
  • Interferon-gamma / metabolism
  • Leukocytes, Mononuclear / immunology
  • Mice
  • Mice, Inbred BALB C
  • Oligodeoxyribonucleotides / administration & dosage*
  • Oligopeptides / administration & dosage*
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • Viral Envelope Proteins / genetics
  • Viral Envelope Proteins / immunology

Substances

  • Adjuvants, Immunologic
  • Antibodies, Viral
  • Antigens, Viral
  • Dengue Vaccines
  • Drug Combinations
  • IC31 adjuvant
  • Immunoglobulin G
  • Oligodeoxyribonucleotides
  • Oligopeptides
  • Recombinant Fusion Proteins
  • Viral Envelope Proteins
  • Interferon-gamma